TNGX - NASDAQ
Tango Therapeutics, Inc.
$21.47
-7.1%Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotTango Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Tango Therapeutics, Inc. Income Statement
TNGX • NASDAQ
| Tango Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
62.4M | 42.1M | 36.5M | 24.9M | 37M | 7.7M | 24.6M | |
GROSS PROFIT | |||||||
(2.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (1.6M) | (32.3M) | |
60.1M | 42.1M | 36.5M | 24.9M | 37M | 6M | -7.6M | |
OPERATING INCOME | |||||||
(171.4M) | (187.7M) | (150.7M) | (135.9M) | (95.2M) | (58.2M) | (7.2M) | |
(41.5M) | (43.7M) | (35.5M) | (30M) | (17.6M) | (8.2M) | (7.5M) | |
(132.2M) | (143.9M) | (115.2M) | (105.9M) | (77.6M) | (50M) | (32.3M) | |
-111.3M | -145.6M | -114.2M | -111.1M | -58.2M | -52.2M | -15.2M | |
PRE-TAX INCOME | |||||||
5.6M | 7.9M | 6.6M | 1.5M | 495K | 108K | 0.0 | |
-2.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
9.7M | 15.5M | 12.6M | 2.9M | 247K | 228K | 1.1M | |
-101.6M | -130.1M | -101.6M | -108.1M | -57.9M | -52M | -14.1M | |
NET INCOME | |||||||
(4K) | (208K) | (134K) | (54K) | (292K) | (0.0) | (0.0) | |
-101.6M | -130.3M | -101.7M | -108.2M | -58.2M | -52M | -14.1M |
SEC Filings
TNGX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 02, 2026 | 2026 | |
S-3 S-3 N/A | November 21, 2025 | November 21, 2025 |
Related Guides
Continue your TNGX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.